Prospective observational study to evaluate the efficacy and safety of the pollen extract Serelys (R) in the management of women with menopausal symptoms
Abstrakt
Safety concerns or contraindications to the use of hormones have resulted in a rise of the use of herbal medicinal products for the management of menopausal symptoms. The pollen extract SerelysA (R) represents, due to its ingredients and mode of action, a new and innovative alternative for the management of these symptoms.
The aim of the present study was to demonstrate the efficacy and safety of SerelysA (R). A prospective, open, observational, and multicentre study was performed on 104 menopausal women.
The patients received over 3 months the pollen extract SerelysA (R) containing the extracts PI82 and GC Fem in a dosage of twice 160 mg extract and 5 mg vitamin E. Using a validated menopausal rating score, the improvement of menopausal symptoms was recorded.
A significant decrease of different menopausal symptoms was observed between the starting point of the study and after 12 weeks (p < .0001). Hot flashes were reduced by 48.5%, sleep disturbance by 50.1%, depressive mood by 51.2%, irritability by 47.9%, fatigue by 47.8%, vaginal dryness by 39.63% and muscles and joint pain by 27.4%.
The pollen extract SerelysA (R) reduced significant menopausal symptoms showing a very low side effect profile.